Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 4/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18285281 | 0.86 | JAK2 (0.40) | P2RY14HDAC2JAK2ANO1 | |
| SCHEMBL19656299 | 0.85 | P2RY14 (0.50) | P2RY14TRPV1JAK2AKR1C3RXRA | |
| SCHEMBL18285297 | 0.84 | P2RY14 (0.49) | P2RY14TRPV1HDAC2JAK2DHODH | |
| SCHEMBL29727643 | 0.84 | P2RY14 (0.49) | P2RY14TRPV1HDAC2JAK2DHODH | |
| SCHEMBL18285294 | 0.83 | CNR1 (0.46) | JAK2ANO1 | |
| SCHEMBL21003937 | 0.81 | AKR1C3 (0.41) | JAK2AKR1C3RXRARXRB | |
| SCHEMBL18496626 | 0.81 | POLB (0.41) | JAK2ANO1 | |
| SCHEMBL18285327 | 0.80 | P2RY14 (0.48) | P2RY14 | |
| SCHEMBL7753604 | 0.79 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL18496579 | 0.79 | POLB (0.47) | P2RY14HDAC2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563049-B | Imidazole compounds as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-109071451-B | Pyrazole compounds as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-107531642-B | Imidazole derivatives | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | disclosed |
| EP-3526201-B1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-11-18 | — | — | EP | disclosed |
| EP-3526201-B1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-11-18 | — | — | EP | disclosed |
| CN-107922391-B | Pyridine and pyrimidine derivatives | 豪夫迈·罗氏有限公司 | 2020-09-25 | — | — | CN | disclosed |
| EP-3464246-B1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-08 | — | — | EP | disclosed |
| EP-3464246-B1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-08 | — | — | EP | disclosed |
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-02-11 | — | — | US | disclosed |
| EP-3334727-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-06-20 | — | — | EP | disclosed |
| US-20180162824-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| WO-2018069362-A1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-04-19 | — | — | WO | disclosed |
| WO-2018069362-A1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-04-19 | — | — | WO | disclosed |
| EP-3303299-A1 | IMIDAZOLE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | disclosed |
| WO-2017202896-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017202896-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017025523-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-02-16 | — | — | WO | disclosed |
| WO-2016193235-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162824-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | MC3R, MC2R, NPY1R | P2RY14 904/4885TRPV1 2575/4885HDAC2 1599/4885 |
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | DRD3, GABRR3, DRD4 | P2RY14 3572/4885TRPV1 1837/4885HDAC2 168/4885 |
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | SLC1A1, SLC1A3, SLC1A2 | P2RY14 2903/4885TRPV1 802/4885HDAC2 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.